These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 10340921)

  • 41. Intragastric acidity during administration of generic omeprazole or esomeprazole - a randomised, two-way crossover study including CYP2C19 genotyping.
    Miehlke S; Löbe S; Madisch A; Kuhlisch E; Laass M; Grossmann D; Knoth H; Morgner A; Labenz J
    Aliment Pharmacol Ther; 2011 Feb; 33(4):471-6. PubMed ID: 21175704
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers.
    Shimatani T; Inoue M; Kuroiwa T; Moriwaki M; Xu J; Ikawa K; Morikawa N; Tazuma S
    Dig Dis Sci; 2007 Feb; 52(2):390-5. PubMed ID: 17211705
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism.
    Hokari K; Sugiyama T; Kato M; Saito M; Miyagishima T; Kudo M; Nishikawa K; Ishizuka J; Komatsu Y; Mizushima T; Kagaya H; Hige S; Takeda H; Asaka M
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1479-84. PubMed ID: 11552922
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
    Klotz U
    Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism.
    Ieiri I; Kishimoto Y; Okochi H; Momiyama K; Morita T; Kitano M; Morisawa T; Fukushima Y; Nakagawa K; Hasegawa J; Otsubo K; Ishizaki T
    Eur J Clin Pharmacol; 2001 Sep; 57(6-7):485-92. PubMed ID: 11699613
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The effect of proton pump inhibitor on intragastric acidity and it relation to S-mephenytoin hydroxylase genetic polymorphism].
    Wang H; Nie YQ; Dai SJ; She QZ; Li YY
    Zhonghua Nei Ke Za Zhi; 2003 Nov; 42(11):777-80. PubMed ID: 14636465
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acid-suppressive effects of various regimens of omeprazole in Helicobacter pylori-negative CYP2C19 homozygous extensive metabolizers: which regimen has the strongest effect?
    Shimatani T; Kuroiwa T; Moriwaki M; Xu J; Tazuma S; Inoue M
    Dig Dis Sci; 2007 Oct; 52(10):2826-32. PubMed ID: 17410461
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
    Sugimoto M; Furuta T; Shirai N; Kajimura M; Hishida A; Sakurai M; Ohashi K; Ishizaki T
    Clin Pharmacol Ther; 2004 Oct; 76(4):290-301. PubMed ID: 15470328
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations.
    Kita T; Sakaeda T; Aoyama N; Sakai T; Kawahara Y; Kasuga M; Okumura K
    Biol Pharm Bull; 2002 Jul; 25(7):923-7. PubMed ID: 12132671
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study.
    Balian JD; Sukhova N; Harris JW; Hewett J; Pickle L; Goldstein JA; Woosley RL; Flockhart DA
    Clin Pharmacol Ther; 1995 Jun; 57(6):662-9. PubMed ID: 7781266
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection.
    Furuta T; Sagehashi Y; Shirai N; Sugimoto M; Nakamura A; Kodaira M; Kenmotsu K; Nagano M; Egashira T; Ueda K; Yoneyama M; Ohashi K; Ishizaki T; Hishida A
    Clin Gastroenterol Hepatol; 2005 Jun; 3(6):564-73. PubMed ID: 15952098
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype.
    Tanaka M; Ohkubo T; Otani K; Suzuki A; Kaneko S; Sugawara K; Ryokawa Y; Hakusui H; Yamamori S; Ishizaki T
    Clin Pharmacol Ther; 1997 Dec; 62(6):619-28. PubMed ID: 9433390
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin.
    Rost KL; Brösicke H; Brockmöller J; Scheffler M; Helge H; Roots I
    Clin Pharmacol Ther; 1992 Aug; 52(2):170-80. PubMed ID: 1505152
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects.
    Williams MP; Sercombe J; Hamilton MI; Pounder RE
    Aliment Pharmacol Ther; 1998 Nov; 12(11):1079-89. PubMed ID: 9845397
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.
    Sheu BS; Kao AW; Cheng HC; Hunag SF; Chen TW; Lu CC; Wu JJ
    Aliment Pharmacol Ther; 2005 Feb; 21(3):283-8. PubMed ID: 15691303
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
    Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y
    Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19.
    Chang M; Tybring G; Dahl ML; Götharson E; Sagar M; Seensalu R; Bertilsson L
    Br J Clin Pharmacol; 1995 May; 39(5):511-8. PubMed ID: 7669487
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment.
    Rost KL; Brockmöller J; Esdorn F; Roots I
    J Hepatol; 1995 Sep; 23(3):268-77. PubMed ID: 8550990
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole.
    Caraco Y; Wilkinson GR; Wood AJ
    Clin Pharmacol Ther; 1996 Oct; 60(4):396-404. PubMed ID: 8873687
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese].
    He XX; Zhao YH; Hao YT
    Zhonghua Nei Ke Za Zhi; 2004 Jan; 43(1):13-5. PubMed ID: 14990013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.